Obi Pharma Inc.

Yin-Cheng Hsieh

Cheng-Der Tony Yu

Shu-Yi Lin

Yih-Huang Hsieh

Yi-Chien Tsai

Nan-Hsuan Wang

Teng-Yi Huang

Chin-Sheng Chao

Yih Huang Hsieh

Ming-Tain Lai

Pu-Ling Hu

A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The 'R-form' compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the 'S-form' compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.

Methods of making high enantioselective secondary alcohols

The present disclosure relates to novel glycosynthase enzymes for glycoprotein engineering and/or homogeneous antibody remodeling. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and/or modification activity at the conserved N297 glycosylation site of Fc region of an exemplary antibody. It has been demonstrated that the glycosynthase activities of EndoSd-D232M and EndoSz-D234M can be applied to various mAbs targeting different receptors, including, but not limited to, Globo H, SSEA-4, SSEA-3 series of receptors (OBI-888; Globo H ganglioside), Herceptin (Her 2 receptor), Perj eta (Her 2 receptor) and Vectibix (EGFR receptor). It has been found that both mAb-GlcNAc and mAb-GlucNAc(F) were suitable substrates for both EndoSd-D232M and EndoSz-D234M. The ADCC assay of related products, OBI-888-G2S2 and Herceptin-G2S2, showed that the remodeled homogeneous antibody, mAb-G2S2, has an increased relative activity ranging from 3 to 26 folds.

Glycosynthase variants for glycoprotein engineering and methods of use

Growing community of inventors

Taipei, Taiwan

Yin-Cheng Hsieh